MyJournals Home  

RSS FeedsPrognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience (BMC Cancer)

 
 

22 january 2015 06:37:50

 
Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience (BMC Cancer)
 


Background: SBA is a rare tumour which carries a poor prognosis. Very few data on prognostic factors and treatment outcomes are available. We conducted a retrospective analysis of patients treated for SBA at our institution. Methods: Clinico-pathological characteristics, treatments and outcomes of all the SBA patients treated consecutively from 1996 to 2011 were retrospectively collected. The prognostic value of baseline factors was assessed using the Cox regression model. The Kaplan-Meier method was used to estimate the survival outcomes. Results: Eighty-four patients with SBA were treated during the study period. Of these, 48 presented with early stage SBA, while 36 had unresectable disease. All early stage SBA patients (58.3% males; median age, 59?years) underwent resection (R0 in 44/48) and 27 (56%) received adjuvant chemotherapy. Median relapse-free survival and overall survival (OS) were 31.1?months (95% CI: 8.0-54.3) and 42.9 (95% CI: 0?94.9), respectively. In univariate analyses, poor histological differentiation (p?=?0.025) and lymphovascular invasion (p?=?0.003) were prognostic for OS. In the group of patients with relapsed, unresectable or metastatic disease (n?=?59), systemic chemotherapy was administered in 46 cases (78%). The response rate to first line chemotherapy was 50%. Median progression-free survival and OS were 8.8 (95% CI: 5.5-12.3) and 12.8?months (95% CI: 8.4-17.2), respectively. In univariate analyses, low albumin (p?=?0.041) and high platelet count (p?=?0.007) were prognostic for OS. Conclusion: Prospective clinical trials are needed to inform the management of SBA patients. Prognostic factors evaluated in our series may be useful for patient stratification and treatment selection in future studies.


 
87 viewsCategory: Oncology
 
Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer (Breast Cancer Research)
Targeting RNA polymerase I to treat MYC-driven cancer (Oncogene)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:

Oncology


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten